RUNX2 and breast cancer: Targeting RUNX2 can be a highly effective and useful strategy for BC treatment: this approach may exhibit less side effects than conventional chemotherapy and has the potential for high therapeutic index because RUNX2 is normally not expressed in differentiated bone or mature glandular tissues, such as breast [17, 41] and prostate [42].